



I hereby certify that this correspondence is being submitted with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on June 21, 2002

James F. McBride

Name of Attorney or Agent

43,784

Registration No.

Signature of Attorney or Agent

DT16 Rec'd PETIPTO JUN 25 2002

PCT

P&G Case 7806

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Peter Robert Foley et al. : Confirmation No. not assigned
Serial No. 10/089,335 : Group Art Unit not assigned
Filed March 27, 2002 : Examiner not assigned

For Detergent Compositions With Perfume Complexes to Mask Malodors

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97(b)(3) - (>3 mo. after filing direct at 1st stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. § 1.97(c) with fee payment - (use after Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. § 1.97(c). Applicant(s) have not received a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. § 1.17(p). Please charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. § 120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. § 1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s ____, were submitted and considered in parent application U.S. Patent Application Serial No. ____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. § 120. Accordingly, copies of document No.'s ____ are not provided with this Statement, pursuant to 37 C.F.R. § 1.98(d). Copies of document No.'s ____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (4) Pursuant to 37 C.F.R. § 1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.


☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By


James W. McBride
Attorney or Agent for Applicant(s)
Registration No. 43,784
(513) 627-0079

Date: June 21, 2002

Customer No. 27752

(IDS.doc)
(Last Revised 12/7/01)



COPENDING APPLICATIONS

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
7167M	09/701,802	Vinson et al.	2/5/1999
7408	09/890,672	Clarke et al.	2/8/2000

[ones that are pending at time of this filing; others that have issued get cited on the PTO/SB08.]

Please type a plus sign (+) inside this box → (+)

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/089,335
		Confirmation Number	Not assigned
		Filing Date	March 27, 2002
		First Named Inventor	Clarke et al.
		Group Art Unit	Not assigned
		Examiner Name	Not assigned
		Attorney Docket Number	7806

SHEET 1 of



U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-5,578,563	11/26/1996	Trinh et al.	
	2	US-5,102,564	4/7/1992	Gardlik et al.	
	3	US-5,234,610	8/10/1993	Gardlik et al.	
	4	US-5,624,666	4/29/1997	Coffindaffer et al.	
	5	US-5,919,400	7/6/1999	Kim et al.	
	6	US-5,804,219	9/8/1998	Trinh et al.	
	7	US-5,108,660	4/28/1992	Michael	
	8	US-3,929,678	12/30/1975	Laughlin et al.	
	9	US-5,415,814	5/16/1995	Ofosu-Asante et al.	
	10	US-4,316,824	2/23/1982	Pancheri	
	11	US-5,075,501	12/24/1991	Borland et al.	
	12	US-5,071,594	12/10/1991	"	
	13	US-5,739,092	4/14/1998	Ofosu-Asante	
	14	US-3,812,044	5/21/1974	Connor et al.	
	15	US-4,704,233	11/3/1987	Hartman et al.	
	16	US-4,753,570	6/28/1988	Jarvis	
	17	US-4,767,558	8/30/1988	Ouhadi et al.	
	18	US-4,722,413	2/2/1988	Okubo	
	19	US-4,889,652	12/26/1989	Sullivan et al.	
	20	US-4,892,673	1/9/1990	Dixit et al.	
	21	US-4,988,462	1/29/1991	Schepers et al.	
	22	US-5,266,233	11/30/1993	Houghton et al.	
	23	US-4,615,820	10/7/1986	Hepworth et al.	
	24	US-4,292,211	9/29/1981	Herman	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁵
	25	WO 99/27058			6/3/1999	Procter & Gamble		
	26	WO 94/18314			8/18/1994	Genencor Intern'l.		
	27	WO 94/02597			2/3/1994	Novo Nordisk		
	28	GB 2,158,838 A			11/20/1985	Colgate-Palmolive Co.		
	29	GB 2,195,125 A			3/30/1988	"		
	30	GB 2,195,649 A			4/13/1988	"		
	31	EP 225 654			7/19/1989	Unilever		
	32	EP 510 762 B1			3/6/1996	"		
	33	EP 540 089 A1			5/5/1993	"		
	34	EP 540 090 A2			5/5/1993	"		
	35	EP 565 017 B1			7/7/1999	Solvay Interlox Ltd.		
	36	EP 030 096 B2			7/14/1993	Imperial Chemical		
	37	EP 965 326 A			12/22/1999	Procter & Gamble		
	38	WO 00/55288 A			9/21/2000	"		
	39	GB 2,311,296 A			9/24/1997	"		
	40	DD 292 477 A5						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	41	Abstract XP-002158365	
	42	Abstract XP-002158366	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.